MTOR and head and neck squamous cell carcinoma: However, this study did also demonstrate that when mTOR inhibitors were used in conjunction with chemoradiotherapy, response rates improved dramatically to 48.1%, indicating that mTOR inhibitors may be incorporated into treatment for HNSCC in combination with other agents for synergistic effect [40].